Related Experiment Video

Updated: May 4, 2026

Pseudomonas aeruginosa Induced Lung Injury Model
07:24

Pseudomonas aeruginosa Induced Lung Injury Model

Published on: October 29, 2014

18.1K

PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury

Qin Wang1, Huayin Li1, Jian Zhou1

  • 1Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Respiratory Physiology & Neurobiology
|January 15, 2014
PubMed

Insights

Blocking PcrV, a Type III secretion system (TTSS) component, shows promise against multi-drug resistant Pseudomonas aeruginosa. Anti-PcrV antibodies improved survival and reduced lung injury in a mouse model, suggesting a potential therapeutic strategy.

Area of Science:

  • Microbiology
  • Immunology
  • Pulmonary Medicine

Background:

  • Type III secretion system (TTSS) is crucial for Pseudomonas aeruginosa pathogenesis.
  • PcrV is a key component of the TTSS, and blocking it has shown efficacy against laboratory strains.
  • The effectiveness of anti-PcrV strategies against clinically isolated multi-drug resistant (MDR) strains remains unclear.

Purpose of the Study:

  • To investigate the expression level of TTSS in clinical MDR P. aeruginosa isolates.
  • To evaluate the efficacy of anti-PcrV antibodies in a murine model of MDR P. aeruginosa-induced acute lung injury (ALI).

Main Methods:

  • Quantified TTSS expression in 53 P. aeruginosa isolates (25 MDR, 28 susceptible).
  • Utilized a murine model by intratracheal instillation of a MDR strain.
  • Assessed the impact of anti-PcrV antibody on survival, bacterial load, and lung pathology.

Main Results:

  • TTSS expression levels were comparable between MDR and susceptible P. aeruginosa strains.
  • Anti-PcrV antibody administration significantly improved survival rates in challenged mice.
  • Treatment with anti-PcrV reduced bacterial burden and attenuated lung inflammation and injury.

Conclusions:

  • TTSS expression is similar in MDR and susceptible P. aeruginosa.
  • Anti-PcrV antibody is a potential therapeutic candidate for treating MDR P. aeruginosa-induced ALI.
  • This strategy warrants further investigation for clinical application against resistant bacterial infections.
Keywords:
Mab166Multi-drug resistancePcrVPseudomonas aeruginosaType III secretion system

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

17.4K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.0K

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.5K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K